BioTransplant regulatory update

BTRN received notices of allowance for four patents covering its AlloMune and XenoMune systems. AlloMune facilitates the transplant of mismatched human organs, while XenoMune aids in the transplant of porcine organs.

Two allowed U.S. patents will issue to Massachusetts General Hospital and are exclusively licensed to BTRN. One covers a gene therapy method to achieve specific transplant tolerance in both AlloMune and XenoMune systems, while a second patent covers porcine IL-10, an immunomodulatory molecule. ...